Recruiting
Ventilation and Perfusion in Asthmatics
Assess regional changes to perfusion and ventilation from inhaled corticosteroid (ICS) and Fast-acting beta-antagonist (FABA) among adult asthmatics using radiographically derived estimates of regional ventilation (V-distribution), ventilation defect percentage (VDP), and ventilation heterogeneity (VH).
ClinicalTrials.gov IDNCT07426458
PhasePHASE4
Enrollment40
SponsorUniversity of Miami
Age18 Years
SexALL
Conditions studied
Asthma
About this study
Assess regional changes to perfusion and ventilation from inhaled corticosteroid (ICS) and Fast-acting beta-antagonist (FABA) among adult asthmatics using radiographically derived estimates of regional ventilation (V-distribution), ventilation defect percentage (VDP), and ventilation heterogeneity (VH).
Interventions
- Drug: Albuterol Sulfate — Visit 1: Albuterol Sulfate (90mcg) two puffs will be administered via metered-dose inhaler (MDI) with spacer during the baseline study visit to obtain baseline imaging values.
- Drug: Albuterol-Budesonide — Visit 2: AIRSUPRA (Albuterol/Budesonide) (90mcg/80mcg) two puffs will be administered via MDI with spacer during this study visit. This intervention is used to evaluate its effect on ventilation defect percentage (VDP), ventilation heterogeneity (VH), and perfusion metrics derived from XV LVAS imaging
Primary outcomes
- Change in Regional Ventilation (Baseline, 30 minutes after budesonide administration)
Eligibility information
Inclusion Criteria:
* Physician diagnosis of asthma
* Baseline Forced Expiratory Volume in 1 Second (FEV1) \< 80% of predicted, with reversibility (10%) on post-bronchodilator spirometry
* Adults, 18-75 years of age
* Long-term inhaled controller medication consisting of or including an Inhaled corticosteroids (ICS) at a steady dose for at least 3 months before enrollment
Exclusion Criteria:
* Current cigarette smoking or a past history of \>10 pack-year smoking
* Current nicotine vaping
* Pregnant and breast-feeding women
* Respiratory infection within 4 weeks of proposed study date
* Forced Expiratory Volume in 1 Second (FEV1) \< 50%
* Inhaled corticosteroids (ICS)/fast-acting beta agonist (FABA) intolerance
* Use of beta-blockers
* Use of systemic glucocorticosteroids or oral methyl-xanthines within 30 days of planned study visit.
Study locations
- University of Miami - Converge Miami, Miami, Florida 33136 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.